Cardiotoxicity of newer HER2-Directed therapies in breast cancer: A systematic review and meta-analysis of incidence and comparative risk.
BreastJul 20, 2026 (epub)
Senthamizhan Sundaramoorthy, Narendhar Gokulanathan, Rona Joseph P et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the incidence and comparative risk of cardiotoxicity associated with newer HER2-targeted therapies versus trastuzumab-based regimens in 35,984 patients. The pooled cardiotoxicity incidence was 5.08%, with no significant difference in risk between the therapies (RR, 0.97; 95% CI, 0.73 to 1.29).
Key findings
- Pooled cardiotoxicity incidence was 5.08% (95% CI, 3.37 to 7.58).
- Left ventricular ejection fraction (LVEF) decline occurred in 4.68% of patients.
- No significant difference in cardiotoxicity was found between newer therapies and trastuzumab regimens (RR, 0.97; 95% CI, 0.73 to 1.29).
- Higher incidence of cardiotoxicity was noted with more frequent cardiac monitoring (8.15%; 95% CI, 3.13 to 19.61%).
Why it matters
Understanding the cardiotoxicity associated with HER2-targeted therapies is crucial for managing breast cancer patients, as it informs monitoring strategies and helps mitigate potential cardiac risks during treatment.